Cardiovascular risk and safety evaluation of a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, aleglitazar, in patients with type 2 diabetes: A meta-analysis - Han, C L; Qu, C Z (J Cardiovasc Pharmacol, 2020)